-+ 0.00%
-+ 0.00%
-+ 0.00%

Brogidirsen (NS-089/NCNP-02) 5-Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2026 World Muscle Society Congress

Barchart·10/01/2026 06:03:00
Listen to the news

PARAMUS, N.J., Oct. 1, 2026 /PRNewswire/ -- NS Pharma, Inc. (Headquarters: Paramus, New Jersey; President: Yukiteru Sugiyama), a biopharmaceutical leader in rare disease and subsidiary of Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto, Japan; President: Toru Nakai), announced today that the National Center of Neurology and Psychiatry (NCNP, Kodaira City; President, Kazuyuki Nakagome) presented 5-year efficacy and safety data from the open-label extension of an investigator-initiated clinical trial of brogidirsen (NS-089/NCNP-02) for the treatment of Duchenne muscular dystrophy (DMD) at the 31st annual International Congress of the World Muscle Society held in Hiroshima, Japan from September 29 to October 3, 2026.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.